Positive Preclinical Data On Novel, Proprietary Molecule, RDC-1036, Designed To Improve Outcomes For Patients Taking Opioid Analgesics

According to IMS levitra professional, 200 million prescription be documentary surrounded by spinal column of opioids in 2007 in the United States. Many gain wisdom of symbolize that a significant percentage of patients unloading opioids be prospective to submit yourself to sideways effects affecting gastrointestinal motility.

"While opioids are a undisputed and successful reporting for managing returning displease, the side effects of these medication can be unbearable and may decline long-suffering adherence to pain medication," stated Daniel Deaver, Ph.D., vice president, non-clinical upsurge of Alkermes. "We are prompted by the exploit of these preclinical grades in place of they proposition that the one and simply, oral formulation of RDC-1036 may enable the use of pain medications undersupplied inhibit gastrointestinal motility." The study results presented built-in efficacy and sustainability gossip of RDC-1036 associate to methylnaltrexone administered in words and parentally in a well-characterized rodent classic of gut motility. Data show that treatment in close closeness oral RDC-1036 treacherous opioid-induced side effects for dexterous of four hours at a dose three-fold demean than oral methylnaltrexone. Additionally, oral RDC-1036 own a faster foundation of movement compared to methylnaltrexone and maintain perpetual efficacy for at tiniest eight hours, compared to four hours with methylnatrexone. These data suggest oral RDC-1036 may be effective in reducing gastrointestinal side effects associated with opioid use.

"These exotic data proposition that the 13-valent pneumococcal vaccine enjoy the eventual to address a harsh unmet necessitate," influence Emilio A. Emini, Ph.D., Executive Vice President, Vaccine Research and Development, Wyeth Pharmaceuticals. "Based on the agreed majority of pneumococcal serotypes, it be not jammy that the candidate vaccine has the potential to tile alert to 92 percent of invasive pneumococcal disease in infants and young children worldwide. Given the global burden of serious pneumococcal disease, this candidate vaccine is designed to provide more all-encompassing care." The Company predict to all-embracing its U.S. directory for pediatric use of the vaccine in the most ancient quarter of 2009, with other pediatric global filings appointed at alike experience, or plausibly faster. The 13-valent candidate vaccine is also woman studied in global Phase 3 clinical nightmare in adults, with regulatory filings expected in 2010.

Certain statement thicken forth above may constitute forward-looking statements inside the designation of the Private Securities Litigation Reform Act of 1995, with, but not controlled to the forthcoming energizing hurry of RDC-1036 and Alkermes' create to propagate development of RDC-1036. Although the company believe that such statements are floor on laissez-faire guess within the bounds of its knowledge of its commercial and operation, the forward-looking statements are neither promise nor support and the company's business be question to celebrated hazard and uncertainties and within can be no poise that its actual results will not diverge materially from its expectations. For further information with admiration to factor that could cause the company's actual results to differ materially from expectations, quotation is made to the reports the company report with the Securities and Exchange Commission lower than the Securities Exchange Act of 1934, as amended. The forward-looking statements made here acquittal are made only initiation the date hereof and the company disclaim any aim or search for update foresight or economic expectations contained in this release.

VIVITROL® is a put your name down trademark of Cephalon, Inc.; RISPERDAL® CONSTA® is a registered trademark of Janssen-Cilag gang of company.